Mutant idh1 regulates the tumor-associated immune system in gliomas

Genes and Development

Volumn 31, Issue 8, 2017, Pages 774-786

  Amankulor, Nduka M ^a   Kim, Youngmi ^b   Arora, Sonali ^b   Kargl, Julia ^b,c   Szulzewsky, Frank ^b   Hanke, Mark ^b   Margineantu, Daciana H ^b   Rao, Aparna ^a   Bolouri, Hamid ^b   Delrow, Jeff ^b   Hockenbery, David ^b   Houghton, A McGarry ^b,d   Holland, Eric C ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Glioma; IDH mutation; Immuno oncology

Indexed keywords

2 HYDROXYGLUTARIC ACID; B7 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD163 ANTIGEN; CD20 ANTIGEN; CD31 ANTIGEN; CD86 ANTIGEN; CXCL1 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; ISOCITRATE DEHYDROGENASE 1; KI 67 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PLATELET DERIVED GROWTH FACTOR; PROTEIN; PROTEIN P53; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; CD45 ANTIGEN; ISOCITRATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; B LYMPHOCYTE; CANCER GENETICS; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CPG ISLAND; DENDRITIC CELL; DNA METHYLATION; DOWN REGULATION; GENE REPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MACROPHAGE; MEMORY T LYMPHOCYTE; MICROGLIA; MONOCYTE; MOUSE; MUTANT; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; WILD TYPE; ANIMAL; BRAIN TUMOR; CHEMOTAXIS; DISEASE MODEL; ENZYMOLOGY; GENETICS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIGENS, CD45; BRAIN NEOPLASMS; CHEMOTAXIS; DISEASE MODELS, ANIMAL; DNA METHYLATION; GLIOMA; HUMANS; IMMUNE SYSTEM; ISOCITRATE DEHYDROGENASE; LEUKOCYTES; MICE; MUTATION; NEUTROPHIL INFILTRATION; NEUTROPHILS;

EID: 85019852504     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.294991.116     Document Type: Article

References (46)

1. Akalin A, Kormaksson M, Li S, Garrett-Bakelman FE, Figueroa ME, Melnick A, Mason CE. 2012. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol 13: R87.
2. Badie B, Schartner JM. 2000. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46: 957–961.
3. Bai H, Harmanci AS, Erson-Omay EZ, Li J, Coskun S, Simon M, Krischek B, Ozduman K, Omay SB, Sorensen EA, et al. 2016. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet 48: 59–66.
4. Bolouri H, Zhao LP, Holland EC. 2016. Big data visualization identifies the multidimensional molecular landscape of human gliomas. Proc Natl Acad Sci 113: 5394–5399.
5. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. 2013. The somatic genomic landscape of glioblastoma. Cell 155: 462–477.
6. The Cancer Genome Atlas Research Network. 2015. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372: 2481–2498.
7. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, et al. 2016. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164: 550–563.
8. Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, et al. 2014. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc Natl Acad Sci 111: 14217–14222.
9. Coffelt SB, Wellenstein MD, de Visser KE. 2016. Neutrophils in cancer: neutral no more. Nat Rev Cancer 16: 431–446.
10. Cui D, Ren J, Shi J, Feng L, Wang K, Zeng T, Jin Y, Gao L. 2016. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/ β-catenin signaling. Int J Biochem Cell Biol 73: 72–81.
11. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. 2001. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocy-tomas from neural progenitors and astrocytes in vivo. Genes Dev 15: 1913–1925.
12. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739–744.
13. Du P, Kibbe WA, Lin SM. 2008. lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547–1548.
14. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, et al. 2015. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372: 2499–2508.
15. Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suva ML, Bernstein BE. 2016. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529: 110–114.
16. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. 2012. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12: 253–268.
17. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC. 2009. Modeling adult gliomas using RCAS/t-va technology. Transl Oncol 2: 89–95.
18. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, et al. 2010. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120: 707–718.
19. Holland EC, Varmus HE. 1998. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci 95: 1218–1223.
20. Holland EC, Hively WP, DePinho RA, Varmus HE. 1998. A con-stitutively active epidermal growth factor receptor cooperates with disruption of G(1) cell-cycle arrest pathways to induce glioma-like lesions in mice. Gene Dev 12: 3675–3685.
21. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, et al. 2010. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 16: 219–223.
22. Kitamura T, Qian BZ, Pollard JW. 2015. Immune cell promotion of metastasis. Nat Rev Immunol 15: 73–86.
23. + T cell accumulation in gliomas. J Clin Invest 127: 1425–1437.
24. Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB. 2010. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 16: 5722–5733.
25. Krueger F, Andrews SR. 2011. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27: 1571–1572.
26. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES, Jaenisch R. 2005. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res 33: 5868–5877.
27. Mi HY, Muruganujan A, Casagrande JT, Thomas PD. 2013. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 8: 1551–1566.
28. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510–522.
29. Nozawa H, Chiu C, Hanahan D. 2006. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multi-stage carcinogenesis. Proc Natl Acad Sci 103: 12493–12498.
30. Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, Holland EC. 2014. Most human non-GCIMP glioblastoma subtypes evolve from a common pro-neural-like precursor glioma. Cancer Cell 26: 288–300.
31. Piaskowski S, Bienkowski M, Stoczynska-Fidelus E, Stawski R, Sieruta M, Szybka M, Papierz W, Wolanczyk M, Jaskolski DJ, Liberski PP, et al. 2011. Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions. Brit J Cancer 104: 968–970.
32. Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat Med 19: 1423–1437.
33. Rakheja D, Mitui M, Boriack RL, DeBerardinis RJ. 2011. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. Pediatr Blood Cancer 56: 379–383.
34. Reiner A, Yekutieli D, Benjamini Y. 2003. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368–375.
35. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio II, Cairns RA, McCracken S, Wakeham A, Haight J, et al. 2012. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26: 2038–2049.
36. Shalapour S, Karin M. 2015. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125: 3347–3355.
37. Shih AH, Holland EC. 2006. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 232: 139–147.
38. Smyth GK. 2005. Limma: linear models for microarray data. In Bioinformatics and computational biology solutions using R and Bioconductor (ed. Gentleman VCR, et al.), pp. 397–420. Springer, New York.
39. Supek F, Bosnjak M, Skunca N, Smuc T. 2011. REVIGO summarizes and visualizes long lists of gene ontology terms. Plos One 6: e21800.
40. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shi-mamura T, Niida A, Motomura K, Ohka F, et al. 2015. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47: 458–468.
41. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebe F, Lelic N, Wiederschain D, Bedel O, Deng GJ, Zhang BL, et al. 2015. Extreme vulnerability of IDH1 mutant cancers to NAD plus depletion. Cancer Cell 28: 773–784.
42. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479–483.
43. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. 2002. Ink4a–Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 62: 5551–5558.
44. Yu GC, He QY. 2016. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst 12: 477–479.
45. Yu GC, Wang LG, Han YY, He QY. 2012. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16: 284–287.
46. Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, et al. 2016. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol 18: 1402–1412.